AIT THERAPEUTICS INC (OTCMKTS:AITB) Reports Increase in Sellers; Strong Momentum for Short Players

The stock of AIT THERAPEUTICS INC (OTCMKTS:AITB) registered an increase of 20% in short interest. AITB’s total short interest was 600 shares in December as published by FINRA. Its up 20% from 500 shares, reported previously.

It closed at $4.1 lastly. It is down 0.00% since December 11, 2017 and is . It has by 0.00% the S&P500.

AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company has market cap of $34.99 million. The companyÂ’s pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis , cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It has a 5.19 P/E ratio. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections.

Another recent and important AIT Therapeutics, Inc. (OTCMKTS:AITB) news was published by Prnewswire.com which published an article titled: “OTC Markets Group Announces Quarterly Index Performance and Rebalancing – PR Newswire” on October 17, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.